'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS

Acceleron/Celgene’s drug was effective across all endpoints in transfusion-dependent beta-thalassemia and myelodysplastic syndromes, but Acceleron CEO Habib Dable notes key secondary endpoints could be most meaningful to doctors treating these patients.